Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 14/20 | 0.71 |
| ▸ | ROCK2 | O75116 | 10/20 | 0.71 |
| ▸ | PAK3 | O75914 | 2/20 | 0.71 |
| ▸ | PRKD3 | O94806 | 7/20 | 0.67 |
| ▸ | PRKCG | P05129 | 7/20 | 0.67 |
| ▸ | PRKCZ | Q05513 | 7/20 | 0.67 |
| ▸ | PRKCB | P05771 | 6/20 | 0.67 |
| ▸ | PRKCA | P17252 | 6/20 | 0.67 |
| ▸ | PRKCH | P24723 | 6/20 | 0.67 |
| ▸ | PRKCI | P41743 | 6/20 | 0.67 |
| ▸ | PRKCE | Q02156 | 6/20 | 0.67 |
| ▸ | PRKCD | Q05655 | 6/20 | 0.67 |
| ▸ | PRKD1 | Q15139 | 6/20 | 0.67 |
| ▸ | PKN1 | Q16512 | 2/20 | 0.67 |
| ▸ | EGFR | P00533 | 5/20 | 0.57 |
| ▸ | PRKACA | P17612 | 5/20 | 0.57 |
| ▸ | PRKACG | P22612 | 4/20 | 0.57 |
| ▸ | PRKACB | P22694 | 4/20 | 0.57 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1649555 | 0.87 | MAP3K11 (0.67) | PRKCQROCK2PAK3PRKD3PRKCG | |
| SCHEMBL30309325 | 0.85 | PRKCQ (0.71) | PRKCQROCK2PRKD3PRKCGPRKCZ | |
| SCHEMBL22765174 | 0.83 | PRKCQ (1.00) | PRKCQROCK2PAK3PRKD3PRKCG | |
| SCHEMBL20865124 | 0.80 | PRKCQ (0.84) | PRKCQROCK2PAK3PRKD3PRKCG | |
| SCHEMBL13169950 | 0.78 | MAP3K11 (0.83) | PRKCQPRKD3PRKCGPRKCZPRKCB | |
| SCHEMBL22765431 | 0.75 | PRKCQ (1.00) | PRKCQROCK2PAK3PRKD3PRKCG | |
| SCHEMBL28786033 | 0.75 | PRKCQ (1.00) | PRKCQROCK2PAK3PRKD3PRKCG | |
| SCHEMBL30207128 | 0.75 | PRKCQ (1.00) | PRKCQROCK2PAK3PRKD3PRKCG | |
| SCHEMBL23259551 | 0.75 | PRKCQ (0.84) | PRKCQROCK2PAK3PRKD3PRKCG | |
| SCHEMBL13169923 | 0.75 | PAK3 (0.84) | PRKCQROCK2PAK3PRKD3PRKCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50880-E1 | Anti-human OX40L antibodies and methods of treatment | KYMAB LIMITED (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20250263492-A1 | ANTIBODIES, USES & METHODS | KYMAB LTD (GB) | 2025-08-21 | — | — | US | disclosed |
| US-20250199010-A1 | BINDER MOLECULES WITH HIGH AFFINITY AND/ OR SPECIFICITY AND METHODS OF MAKING AND USE THEREOF | ALAMAR BIOSCIENCES, INC. (US) | 2025-06-19 | — | — | US | disclosed |
| EP-4562053-A1 | ANTI-KIT ANTIBODY FORMULATIONS AND METHODS | Celldex Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2025106361-A1 | HUMAN NECTIN-4 BINDERS | MERCK SHARP & DOHME LLC (US) | 2025-05-22 | — | — | WO | disclosed |
| US-20250154269-A1 | IL3Ra Antibody Conjugates and Uses Thereof | STEMLINE THERAPEUTICS, INC. (US) | 2025-05-15 | — | — | US | disclosed |
| CN-119948056-A | Anti-KIT antibody formulations and methods | 塞尔德克斯医疗公司 | 2025-05-06 | — | — | CN | disclosed |
| US-20250129159-A1 | METHODS OF TREATING CANCER USING ANTIBODIES AND MOLECULES THAT IMMUNOSPECIFICALLY BIND TO BTN1A1 | STCUBE & CO INC (KR) | 2025-04-24 | — | — | US | disclosed |
| US-20250052758-A1 | RECEPTOR FOR VISTA | PIERRE FABRE MEDICAMENT (FR) | 2025-02-13 | — | — | US | disclosed |
| US-12215151-B2 | Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1 | STCUBE & CO., INC. (KR) | 2025-02-04 | — | — | US | disclosed |
| EP-3265123-B1 | ANTIBODIES, USES & METHODS | KYMAB LTD (GB) | 2022-10-26 | — | — | EP | disclosed |
| EP-4063391-A1 | ANTI-KIT ANTIBODIES AND USES THEREOF | Celldex Therapeutics, Inc. (US) | 2022-09-28 | — | — | EP | disclosed |
| WO-2022159737-A1 | ANTI-KIT ANTIBODIES AND USES THEREOF | CELLDEX THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| US-11396550-B2 | Methods of treating comprising administering anti-OX40L antibodies | KYMAB LIMITED (GB) | 2022-07-26 | — | — | US | disclosed |
| WO-2022147463-A2 | BINDER MOLECULES WITH HIGH AFFINITY AND/ OR SPECIFICITY AND METHODS OF MAKING AND USE THEREOF | ALAMAR BIOSCIENCES, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| CN-114470194-A | Antibodies and molecules that immunospecifically bind to BTN1A1 and therapeutic uses thereof | 斯特库伯株式会社 | 2022-05-13 | — | — | CN | disclosed |
| EP-3113797-B1 | ANTIBODIES, USES&METHODS | KYMAB LTD (GB) | 2022-05-04 | — | — | EP | disclosed |
| US-11292837-B2 | Nectin-4 binding proteins and methods of use thereof | AGENSYS, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| EP-3381943-B1 | ANTI-KIT ANTIBODIES AND USES THEREOF | CELLDEX THERAPEUTICS INC (US) | 2022-03-16 | — | — | EP | disclosed |
| US-11253590-B2 | Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator) | STSCIENCES, INC. (KR) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12215151-B2 | Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1 | CD274, BTN3A1, PDCD1LG2 | PRKCQ 3871/4885ROCK2 4267/4885PAK3 3615/4885 |
| US-20250129159-A1 | METHODS OF TREATING CANCER USING ANTIBODIES AND MOLECULES THAT IMMUNOSPECIFICALLY BIND TO BTN1A1 | CD274, BTN3A1, PDCD1LG2 | PRKCQ 3871/4885ROCK2 4267/4885PAK3 3615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.